Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-027545.pdf
0001415889-24-027545.rtf
0001415889-24-027545.xls
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001950047-24-008942.pdf
0001950047-24-008942.rtf
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001950047-24-008868.pdf
0001950047-24-008868.rtf
0001950047-24-008868.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000080255-24-001418.pdf
0000080255-24-001418.rtf
144/A

Amendment to a previously filed 144

 View HTML
0001966249-24-000018.pdf
0001966249-24-000018.rtf
0001966249-24-000018.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-026594.pdf
0001415889-24-026594.rtf
0001415889-24-026594.xls
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001966249-24-000017.pdf
0001966249-24-000017.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-24-013882.pdf
0001558370-24-013882.rtf
0001558370-24-013882.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-24-013960.pdf
0001558370-24-013960.rtf
0001558370-24-013960.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-024776.pdf
0001415889-24-024776.rtf
0001415889-24-024776.xls